Bayer: AskBio advances clinical trial

(CercleFinance.com) - AskBio advances gene therapy clinical trial for limb-girdle muscular dystrophy type 2I/R9 with dosing of first participant in second cohort.


AskBio is a wholly owned and independently operated gene therapy company and a subsidiary of Bayer.

The Data Safety Monitoring Board (DSMB) recommendation to initiate a second cohort follows the review of safety data from the Phase 1/Phase 2 LION-CS101 trial for AB-1003. Recruitment of the second cohort is underway.

' The dosing of the first participant in the second cohort of the trial is good news for people living with LGMD2I/R9. This is a rare and debilitating type of muscular dystrophy, and this advance brings the completion of the LION-CS101 trial even closer,' said Nicholas Johnson, MD, Principal Investigator and Vice President for Research in the Department of Neurology at Virginia Commonwealth University School of Medicine.

Copyright (c) 2025 CercleFinance.com. All rights reserved.